Author(s): Gulliver W, Landells IDR, Morgan D, Pirzada S
Unnecessary investigations, inappropriate treatment, worsening disease, and frustration for both patients and health care professionals are the hallmarks of hidradenitis suppurativa (HS) management. In light of a new treatment algorithm and biologic therapies made available to patients, an HS model of care is outlined in this article. The recommendations and management strategy presented here have been developed to help address the currently unmet needs of this patient population. The patient-centred model of care and disease management strategies were developed through the guidance and recommendations of HS medical experts in Newfoundland and Labrador. This article lays the foundation for the resources and steps required to change the status of this orphan disease and firmly embed patients with HS within a coordinated and integrative system of care.
Dermatology Journal and/or Publisher
Journal Name: Journal of cutaneous medicine and surgery
Journal Abbreviation: J Cutan Med Surg
Journal Date Published: 2017-10-23
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/29056071
Lasted Revision: 2017-10-23
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).